This study is testing a medicine called **Siltuximab** for people with schizophrenia. Schizophrenia is a brain disorder that affects how a person thinks, feels, and acts. Siltuximab is a special medicine that targets **interleukin-6 (IL-6)**, a protein involved in inflammation in the body. The study will last for **9 weeks** and is checking if Siltuximab, when added to regular antipsychotic medications, can help improve thinking skills in people with schizophrenia. Participants will receive the medicine through an **intravenous (IV) infusion**, which means it's given directly into a vein.
The study will have 5 visits: screening, baseline, and weeks 3, 6, and 9. Participants will be randomly assigned to receive either Siltuximab or a placebo (a substance with no active medication) along with their current treatment. Risks could include known side effects like fatigue or rash, and serious ones like anaphylaxis or renal failure, though these are rare.
- This is a 9-week study with 5 visits.
- Participants receive 3 IV infusions.
- Potential side effects include fatigue and rash.